vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Palomar Holdings, Inc. (PLMR). Click either name above to swap in a different company.
Palomar Holdings, Inc. is the larger business by last-quarter revenue ($253.4M vs $168.4M, roughly 1.5× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 62.7%). Over the past eight quarters, Palomar Holdings, Inc.'s revenue compounded faster (46.2% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Palomar Holdings, Inc. is a specialty insurance holding company that primarily provides property insurance products for catastrophe-exposed residential and commercial assets. It mainly operates across the United States, focusing on core segments including earthquake, flood, and windstorm coverage to meet high-risk property protection demands of customers.
ESPR vs PLMR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $253.4M |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 28.7% |
| Net Margin | — | — |
| Revenue YoY | 143.7% | 62.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | $2.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $253.4M | ||
| Q3 25 | $87.3M | $244.7M | ||
| Q2 25 | $82.4M | $203.3M | ||
| Q1 25 | $65.0M | $174.6M | ||
| Q4 24 | $69.1M | $155.8M | ||
| Q3 24 | $51.6M | $148.5M | ||
| Q2 24 | $73.8M | $131.1M | ||
| Q1 24 | $137.7M | $118.5M |
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $51.5M | ||
| Q2 25 | $-12.7M | $46.5M | ||
| Q1 25 | $-40.5M | $42.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $30.5M | ||
| Q2 24 | $-61.9M | $25.7M | ||
| Q1 24 | $61.0M | $26.4M |
| Q4 25 | 50.6% | 28.7% | ||
| Q3 25 | -11.4% | 27.4% | ||
| Q2 25 | 8.6% | 29.5% | ||
| Q1 25 | -34.0% | 30.8% | ||
| Q4 24 | -6.4% | 28.9% | ||
| Q3 24 | -31.0% | 25.9% | ||
| Q2 24 | 3.5% | 25.5% | ||
| Q1 24 | 52.5% | 29.0% |
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | 21.0% | ||
| Q2 25 | -15.4% | 22.9% | ||
| Q1 25 | -62.2% | 24.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | 20.5% | ||
| Q2 24 | -83.9% | 19.6% | ||
| Q1 24 | 44.3% | 22.3% |
| Q4 25 | $0.32 | $2.05 | ||
| Q3 25 | $-0.16 | $1.87 | ||
| Q2 25 | $-0.06 | $1.68 | ||
| Q1 25 | $-0.21 | $1.57 | ||
| Q4 24 | $-0.14 | $1.29 | ||
| Q3 24 | $-0.15 | $1.15 | ||
| Q2 24 | $-0.33 | $1.00 | ||
| Q1 24 | $0.34 | $1.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $106.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $942.7M |
| Total Assets | $465.9M | $3.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $106.9M | ||
| Q3 25 | $92.4M | $111.7M | ||
| Q2 25 | $86.1M | $81.3M | ||
| Q1 25 | $114.6M | $119.3M | ||
| Q4 24 | $144.8M | $80.4M | ||
| Q3 24 | $144.7M | $86.5M | ||
| Q2 24 | $189.3M | $47.8M | ||
| Q1 24 | $226.6M | $61.4M |
| Q4 25 | $-302.0M | $942.7M | ||
| Q3 25 | $-451.4M | $878.1M | ||
| Q2 25 | $-433.5M | $847.2M | ||
| Q1 25 | $-426.2M | $790.4M | ||
| Q4 24 | $-388.7M | $729.0M | ||
| Q3 24 | $-370.2M | $703.3M | ||
| Q2 24 | $-344.2M | $532.6M | ||
| Q1 24 | $-294.3M | $501.7M |
| Q4 25 | $465.9M | $3.1B | ||
| Q3 25 | $364.0M | $2.9B | ||
| Q2 25 | $347.1M | $2.8B | ||
| Q1 25 | $324.0M | $2.4B | ||
| Q4 24 | $343.8M | $2.3B | ||
| Q3 24 | $314.1M | $2.3B | ||
| Q2 24 | $352.3M | $2.0B | ||
| Q1 24 | $373.1M | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $409.1M |
| Free Cash FlowOCF − Capex | — | $409.0M |
| FCF MarginFCF / Revenue | — | 161.4% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $700.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $409.1M | ||
| Q3 25 | $-4.3M | $83.6M | ||
| Q2 25 | $-31.4M | $120.9M | ||
| Q1 25 | $-22.6M | $87.2M | ||
| Q4 24 | $-35.0M | $261.2M | ||
| Q3 24 | $-35.3M | $100.3M | ||
| Q2 24 | $-7.2M | $55.1M | ||
| Q1 24 | $53.8M | $33.1M |
| Q4 25 | — | $409.0M | ||
| Q3 25 | — | $83.6M | ||
| Q2 25 | — | $120.8M | ||
| Q1 25 | — | $87.1M | ||
| Q4 24 | — | $260.9M | ||
| Q3 24 | $-35.5M | $100.1M | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | 161.4% | ||
| Q3 25 | — | 34.2% | ||
| Q2 25 | — | 59.4% | ||
| Q1 25 | — | 49.9% | ||
| Q4 24 | — | 167.5% | ||
| Q3 24 | -68.7% | 67.4% | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | 0.1% | 0.0% | ||
| Q1 24 | 0.1% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.63× | ||
| Q2 25 | — | 2.60× | ||
| Q1 25 | — | 2.03× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.29× | ||
| Q2 24 | — | 2.14× | ||
| Q1 24 | 0.88× | 1.26× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PLMR
Segment breakdown not available.
